Drugs / RC278
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07105215 | Aug 2025 → Dec 2027 expected | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-12 | RemeGen Co., Ltd. | Regulatory RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted remegen.com ↗
On May 12th, RemeGen Co., Ltd. (688331.SH/9995.HK) announced that the Clinical Trial Application (CTA) for its novel ADC Drug RC278 has been submitted recently and accepted by National Medical Products Administration (NMPA) Center for Drug Reevaluation (CDE) on May 8th. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-12 | RemeGen Co., Ltd. | RemeGen’s Novel ADC Drug RC278’s Clinical Trial Application Accepted remegen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC278 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07105215 ↗ |
| Route | Intravenous | “Intravenous (IV) administration of RC278 Q3W.” NCT07105215 ↗ |